AUPH
NASDAQ · Biotechnology
Aurinia Pharmaceuticals Inc
$16.41
+0.20 (+1.23%)
Financial Highlights (FY 2026)
Revenue
272.30M
Net Income
276.29M
Gross Margin
88.5%
Profit Margin
101.5%
Rev Growth
+28.3%
D/E Ratio
0.12
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 88.5% | 88.5% | 52.2% | 52.2% |
| Operating Margin | 37.1% | 33.4% | -22.6% | -27.3% |
| Profit Margin | 101.5% | 96.4% | -25.9% | -23.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 272.30M | 212.22M | 554.79M | 498.94M |
| Gross Profit | 240.87M | 187.73M | 289.46M | 260.32M |
| Operating Income | 100.91M | 70.78M | -125,477,129 | -136,428,079 |
| Net Income | 276.29M | 193.80M | -143,878,553 | -118,778,272 |
| Gross Margin | 88.5% | 88.5% | 52.2% | 52.2% |
| Operating Margin | 37.1% | 33.4% | -22.6% | -27.3% |
| Profit Margin | 101.5% | 96.4% | -25.9% | -23.8% |
| Rev Growth | +28.3% | +28.3% | +6.7% | +8.9% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 115.90M | 115.90M | 609.82M | 763.05M |
| Total Equity | 978.87M | 978.87M | 1.36B | 1.29B |
| D/E Ratio | 0.12 | 0.12 | 0.45 | 0.59 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 119.63M | 88.57M | -183,212,536 | -145,145,703 |
| Free Cash Flow | — | — | -112,933,113 | -81,032,986 |